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Abstract
Background—It has recently been reported that atrial fibrillation [AF] is associated with an 
increased risk of myocardial infarction [MI]. However, the mechanism underlying this association 
is currently unknown. Further study of the relationship of AF with type of MI [ST elevation MI 
(STEMI) vs. non-ST elevation MI [NSTEMI] might shed light on the potential mechanisms.
Methods and Results—We examined the association between AF and incident MI in 14,462 
participants [mean age 54 years, 56% women, 26% African Americans] from the Atherosclerosis 
Risk in Communities study who were free of coronary heart disease at baseline [1987–1989] with 
follow-up through December 31, 2010. AF cases were identified from study visits 
electrocardiogram and by review of hospital discharge records. Incident MI and its types were 
ascertained by an independent adjudication committee. Over a median follow up of 21.6 years, 
1374 MI events occurred [829 NSTEMI, 249 STEMI, 296 unclassifiable]. In a multivariable 
adjusted model, AF [n=1545] as a time-varying variable was associated with a 63% increased risk 
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of MI [HR (95% CI):1.63(1.32–2.02)]. However, AF was associated with NSTEMI [HR (95% 
CI): 1.80(1.39–2.31)] but not STEMI [HR (95% CI): 0.49(0.18–1.34)]; p-value for hazard ratios 
comparison=0.004. Combining the unclassifiable MI group with either STEMI or NSTEMI did 
not change this conclusion. The association between AF and MI, total and NSTEMI, was stronger 
in women than in men [interaction p-value<0.01 for both].
Conclusions—AF is associated with an increased risk of incident MI, especially in women. 
However, this association is limited to NSTEMI.
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Introduction
The significance of atrial fibrillation [AF] as a major public health problem stems from its 
increasing prevalence and strong association with poor outcomes. Currently, the number of 
individuals with AF in the United States is estimated as ≈2.7 to 6.1 million, and this is 
expected to double by 2050.1–3 In addition to being an established risk factor for stroke 4, 5, 
a recent study showed that AF is a risk factor for myocardial infarction [MI].6 In the 
Reasons for Geographic and Racial Differences in Stroke [REGARDS] study, AF was 
associated with a 70% increased risk of incident MI after adjustment for several 
cardiovascular risk factors and potential confounders, and the risk was significantly higher 
in women than in men and in blacks than in whites.6 These results are yet to be validated in 
an independent cohort, and the mechanism explaining this association is currently unknown. 
Further study of the relationship of AF with type of MI [ST elevation MI (STEMI) vs. non-
ST elevation MI (NSTEMI] might shed light on the underlying mechanisms. Thus, we 
examined the association between AF and MI [overall and by type] in the Atherosclerosis 
Risk in Communities [ARIC] Study.
Methods
Study Population
The ARIC study is a community-based population study designed to investigate the causes 
of atherosclerosis and its clinical outcomes as well as variation in cardiovascular risk 
factors, medical care, and disease by race and sex.7 From 1987 to 1989 [ARIC study 
baseline], 15,792 adults [55.2% women, 45–64 years of age] from four US communities 
[Washington County, MD; suburbs of Minneapolis, MN; Jackson, MS; and Forsyth County, 
NC] were enrolled and underwent a home interview and clinic visit. Additional exams were 
conducted in 1990–1992, 1993–1995, 1996–1998, and 2011–2013. Participants were mostly 
white in the Washington County and Minneapolis sites, exclusively African American in 
Jackson, and a mix of both in Forsyth County.
For the purpose of this study, we excluded participants with missing or poor quality baseline 
electrocardiograms [ECG] [n=242], missing data on baseline covariates [n=241], race other 
than white or black as well as non-white in the Minneapolis and Washington County sites 
[n=103], and those with prevalent coronary heart disease [history of MI, baseline ECG-
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evidence of MI, or history of coronary bypass or angioplasty] [n=744]. After all exclusions, 
14,462 participants remained and were included in this analysis. The ARIC study was 
approved by the institutional review boards at each participating center, and written 
informed consent was obtained from all participants.
Ascertainment of AF
AF cases were identified from study visit ECGs and by review of hospital discharge 
records.8,9 At each study exam, a standard supine 12-lead resting ECG was recorded with a 
MAC PC Personal Cardiograph [Marquette Electronics, Milwaukee, Wisconsin, USA] and 
transmitted to the ARIC ECG Reading Center [EPICARE Center, Wake Forest School of 
Medicine, Winston Salem, NC] for automatic coding. A cardiologist visually confirmed all 
AF cases automatically detected from the study ECG. Information on hospitalizations during 
follow-up was obtained from annual follow-up calls and surveillance of local hospitals, with 
hospital discharge diagnoses codes collected by trained abstractors. AF during follow-up 
was defined as International Classification of Disease 9th revision, Clinical Modification 
[ICD-9-CM] 427.31 or 427.32 diagnosis codes. AF cases detected in the same 
hospitalization with open cardiac surgery were not included in the AF cases. Hospital 
diagnosis codes for AF ascertainment have been shown to have good positive predictive 
value reaching 98.6%.8, 10, 11
Ascertainment of MI events
MI events were identified by contacting participants annually, identifying hospitalizations 
during the previous year, and by review of all discharge records from all hospitals serving 
the four ARIC field centers.12 Trained ARIC staff members abstracted medical records for 
all hospitalizations. Information obtained from medical records included presence of chest 
pain, history of MI or other cardiovascular-related conditions, and measures of cardiac 
biomarkers [total creatinine phosphokinase (CK), CK-MB, lactate dehydrogenase, and 
troponin]. Elevated cardiac enzymes were considered abnormal if the values are at least 
twice the upper limits of normal, while considered equivocal if they are between the upper 
limit of normal and twice that limit. Copies of up to three ECGs were obtained and sent to 
the University of Minnesota Electrocardiographic Reading Center [Minneapolis, MN] for 
classification according to the Minnesota code.13 A standardized computerized algorithm 
was applied to data on chest pain, cardiac biomarkers, and ECG evidence to determine each 
participant’s computer-based MI diagnosis.14 Cases with disagreements between the 
computer-based diagnosis and discharge diagnosis codes were reviewed by physicians of the 
ARIC Mortality and Morbidity Classification Committee for final classification. All eligible 
hospitalized events were classified as definite, probable, possible or not present. Definite or 
probable MI defined MI event in our analysis. The diagnosis of definite MI was made if one 
or more of the following criteria were met: 1) Evolving diagnostic ECG pattern; 2) 
Diagnostic ECG pattern plus abnormal enzymes; or 3) Cardiac pain and abnormal enzymes 
plus evolving ST-T pattern or equivocal ECG pattern. On the other hand, the diagnosis of 
probable MI must meet one or more of the following criteria in the absence of sufficient 
evidence for definite MI: 1) Cardiac pain and abnormal enzymes; 2) Cardiac pain and 
equivocal enzymes plus either evolving ST-T pattern or diagnostic ECG pattern; or 3) 
Abnormal enzymes and evolving ST-T pattern. MI events were further classified as 
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NSTEMI or STEMI on the basis of the coded ECGs. MI events with missing or equivocal 
ECGs were considered as unclassifiable. For fatal MI events, documentation of MI was 
based on information obtained from the next of kin and other informants including the 
certifying physician, coroner, or medical examiner, or from medical records for any eligible 
hospitalization within 28 days before death. Detailed definition of on MI ascertainment in 
ARIC including details on the definitions of different ECG patterns involved in the 
diagnosis as well as the cut-points for cardiac enzymes could be found at the publically 
available manual of operation of surveillance components procedures in ARIC.15
In this analysis, incident MI event was defined as first occurrence of a fatal or non-fatal MI 
in a participant without evidence of prior MI. Follow-up time was stopped at the time of MI 
occurrence. Therefore, AF events occurring after MI incidence were not included, and those 
MI events were assigned to the non-AF follow-up.
Covariates
Baseline age, sex, race, education level, income and smoking status were determined by 
self-report. Body mass index [BMI] at baseline was calculated as weight [in kilograms] 
divided by height [in meters] squared. Blood samples were obtained after an 8-hour fasting 
period. Diabetes was defined as a fasting glucose level ≥126 mg/dL [or non-fasting glucose 
≥200 mg/dL], a self-reported physician diagnosis of diabetes, or use of diabetes medications. 
Hypertension was defined as systolic blood pressure ≥140 mmHg, diastolic blood pressure 
≥90 mmHg, or use of blood pressure lowering medications. Estimated glomerular filtration 
rate (eGFR) based on creatinine (eGFRcreat) was calculated using the CKD Epidemiology 
Collaboration (CKD-EPI) equation for creatinine.16 At each study visit, medication history 
was obtained by self-report of medication intake during last two weeks and by reviewing 
medications brought by the participants to their visit. Each medication was coded by trained 
and certified interviewers with the use of a computerized medication classification system. 
Prevalent stroke and peripheral arterial disease were identified by self-reported history of a 
previous physician diagnosis. Prevalent heart failure was identified by the Gothenburg 
criteria and/or self-reported history of heart failure medication use in the past two weeks.17
Statistical analysis
Baseline characteristics of the analysis population were tabulated by AF status. Age-
adjusted incidence rates of MI per 1000 person-years in participants with and without AF 
were calculated in the entire analysis population and in sex and race subgroups. In the AF 
group, person-time for the incidence rates was calculated from AF diagnosis to occurrence 
of MI or censoring, while in the non-AF group, person-time was calculated from baseline, 
AF occurrence, MI occurrence, or censoring. Event-free survival probability was estimated 
using Kaplan Meier method and compared using log-rank test by AF status.
Cox proportional hazards regression was used to examine the association between AF as a 
time-varying variable with incident MI [overall, and by MI type] in a series of models with 
incremental adjustments as follows: Model 1 adjusted for age, sex, race, field center, 
education, income; Model 2 adjusted for Model 1 plus baseline BMI, smoking status, total 
cholesterol, HDL cholesterol, systolic blood pressure, blood pressure lowering drugs, 
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diabetes, eGFR, heart failure, prevalent stroke, and prevalent peripheral arterial disease; 
Model 3 adjusted for Model 2 covariates plus time-varying use of statins, warfarin and 
aspirin ascertained at ARIC examinations. We examined the assumption of proportional 
hazards by computation of Schoenfeld residuals, and inspection of log(−log[survival 
function]) curves, and they were met. Individuals were censored at the time of MI, death or 
December 31, 2010, whichever occurred earlier. We compared the association of incident 
AF with STEMI and NSTEMI applying the competing risk approach proposed by Lunn and 
McNeil to an augmented data set. Differences in the association were tested including an 
interaction term between AF incidence and MI type in a stratified Cox model ran in this 
augmented data set.18
Because of the previously reported significant interaction by sex and race,6 models with 
identical incremental adjustment as those described above for the main analysis were 
examined in subgroups by sex and race. Additionally, we examined interaction by age, using 
the median age (≥55 years) at the time of enrollment as a cut-point. Interactions were tested 
including multiplicative terms in the models.
In the analysis by MI type, we excluded the unclassifiable MIs. However, to examine the 
effect of the unclassifiable MIs on the association between AF and type of MI, we 
conducted sensitivity analyses in which we considered the unclassifiable MIs as STEMI in 
one set of analysis and as NSTEMI in another set of analysis. Also, to ensure temporality 
(i.e. occurrence of MI after AF), we conducted another sensitivity analysis in which we 
excluded participants with an MI event occurring within a short period (within a week) after 
a documented AF. Other additional analyses included: 1) Examining the association 
between AF and MI [overall and by type] using Cox proportional models adjusted for 
variables in model 3 plus other possible confounders [heart rate, beta blocker use, 
angiotensin converting enzyme inhibitors use, interim revascularization] all included in the 
models as time-varying covariates; 2) Comparing the association between AF and MI at 
different times of follow up; 3) Plotting the cumulative incidence of AF from baseline 
[1987–1989] to the end of follow up [2010]. The results of these additional analyses are 
provided in the Online-Only Data Supplement.
Statistical significance for all analyses was p<0.05 (two-sided). Analyses were conducted 
using SAS 9.2 [SAS Institute, Cary, NC].
Results
This analysis included 14,462 participants [mean age 54 years, 56% women, 26% African 
Americans] free of coronary heart disease at the time of enrollment, of whom 1,545 had AF 
either at baseline (n= 31) or during follow up (n=1514) before occurrence of an MI event. 
Supplemental Figure 1 shows the cumulative incidence of AF from baseline [1987–1989] to 
the end of follow up [2010], and Supplemental Table 1 shows the incidence rate of AF by 5-
year time interval since baseline.
Table 1 shows the baseline characteristics of the study population at the study baseline 
[1987–1989] stratified by AF status detected at baseline and follow up through 2010. 
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Compared with those without AF by the end of follow up, participants with AF were more 
likely to be older, white, and men with higher prevalence of diabetes, hypertension, and 
prior cardiovascular disease [heart failure, stroke, peripheral arterial disease] at baseline.
Over a median follow up of 21.6 [25th and 75th percentiles = 16.9 and 22.6] years, 1374 
incident MI events occurred. The mean ± SD time from AF diagnosis to MI in those with 
AF was 4.82±4.58 [median 3.35] years. The age adjusted incidence rate of MI was almost 
three-fold higher in those with AF than those without AF [event rate (95%CI): 11.60 
(10.49–12.83) vs. 3.96 (3.71–4.22) per 1000 person-years respectively; incidence rate ratio 
(95%CI): 2.93 (2.61–3.30)]. Figure 1 shows the event (total MI) free survival curves by AF 
status. In subgroup analyses by sex and race, the highest age-adjusted MI incidence rate 
ratios [IRR] by AF status were observed in women [IRR (95%CI): 3.75 (3.14–4.47)] and 
blacks [IRR (95%CI): 3.26 (2.57–4.14)], which compare to IRR (95%CI) of 2.88 (2.52–
3.30) in whites and 2.27 (1.94–2.66) in men (Figure 2). In a socio-demographic adjusted 
Cox proportional hazards model, AF, compared with no AF, was associated with a 92% 
increase in MI risk [p<0.001]. This association remained significant [63% increased risk, 
p<0.001] after further adjustment for traditional cardiovascular risk factors and other 
potential confounders (Table 2). Also, the results were similar when the variables in model 3 
plus other possible confounders/mediators were used in the models as time-varying 
covariates (Supplemental Table 2)
In subgroup analysis, the association between AF and risk of MI was stronger in women 
than in men [interaction p<0.001; Table 2]. Quantitatively, the risk of MI associated with AF 
was stronger in blacks [multivariable HR (95%CI): 2.05 (1.32–3.18)] than in whites 
[multivariable HR (95%CI): 1.52 (1.19–1.94)] but the interaction p-value did not reach 
statistical significance [p=0.16] (Table 2). No significant differences in the association 
between AF and MI stratified by median age [55 years] were observed in Model 3 [HR 
(95%CI): 1.72 (1.17–2.53) for age <55 years and 1.59 (1.23–2.06) for age > 55years; 
interaction p=0.51].
Of 1374 incident MIs that occurred during follow up, 249 were STEMI and 829 were 
NSTEMI. There was no significant difference in the mean time from AF to STEMI [4.29± 
4.58 (median 3.75) years] and NSTEMI [5.07± 4.56 (median 3.59) years]; p-value=0.74. 
Supplemental Figure 2 and Supplemental Figure 3 show the event free survival curves by 
AF status stratified by type of MI. Table 3 shows the relative HR for MI type by AF status. 
As shown, AF was associated with an increased risk of NSTEMI [multivariable HR 
(95%CI): 1.80 (1.39–2.31)] but not STEMI [multivariable HR (95%CI): 0.49, (0.18–1.34)]; 
p-value for comparison of HRs =0.004 using the Lunn-McNeil method. Similar patterns 
were observed in subgroup analysis stratified by sex and race (Table 4). Also, the results 
were similar when the variables in Model 3 plus other possible confounders/mediators were 
used in the models as time-varying covariates (Supplemental Table 3)
In a sensitivity analysis in which unclassifiable MIs (n= 296) were considered as either 
NSTEMI or STEMI, separately, the association between AF with NSTEMI remained 
statistically significant [p<0.001], and with STEMI remained non-significant [p=0.11]. Also, 
the magnitude and direction of the associations between AF with STEMI and NSTEMI in 
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the early years of ARIC [1987–2002] were similar to the associations observed in the later 
years of ARIC follow up [2003–2010]; interaction p-value by period of follow up =0.42 for 
STEMI and 0.44 for NSTEMI (Supplemental Table 4).
Excluding participants [n=72] with an MI event occurring within a week after a documented 
AF did not change our conclusions and only strengthened our results [multivariable adjusted 
HR (95%CI): 1.74 (1.40–2.16), p<0.001 for total MI, 1.91 (1.48–2.47), p<0.001 for 
NSTEMI; and 0.51 (0.18–1.38), p=0.18 for STEMI].
Discussion
In this analysis from the ARIC study, AF was associated with a significantly increased risk 
of incident MI after adjustment for cardiovascular and other risk factors. The association 
was stronger in women than in men. These results accord with the recently reported findings 
from the REGARDS study showing that AF is a risk factor for MI.6 More importantly, 
however, our results from this analysis fill knowledge gaps and address several unanswered 
questions including the effect of MI type and methods of AF ascertainment on the AF and 
MI association. Our results show that the association between AF and MI is limited to 
NSTEMI. This finding may shed light on the underlying mechanism by which AF is linked 
to MI. Although STEMI and NSTEMI have similar long-term prognosis, their 
pathophysiology and treatment differ significantly.19, 20 These different treatment strategies 
stem from the fact that in STEMI the culprit artery usually is occluded completely by a 
thrombus, whereas in NSTEMI the culprit artery is usually patent with a non-occlusive 
thrombus. With that in mind and given our finding that AF is associated with NSTEMI and 
not STEMI suggests that direct coronary thromboembolization is less likely to be the 
primary mechanism by which AF leads to MI. This suggestion accords with the common 
belief that direct coronary thromboembolization is less common because of the anatomical 
obstacles that minimize the possibility of direct coronary embolization e.g. differences 
between the caliber of the aorta and the coronary arteries, location of the coronary vessels at 
the root of the aorta, emergence of the coronary arteries at a right angle, and the fact that the 
major part of coronary filling occurs in diastole.21
The association between AF and NSTEMI also suggests that factors that lead to partial 
occlusion of the coronary arteries or increased oxygen demand are more likely to explain the 
observed association between AF and MI. Hence, AF-induced increase in peripheral 
prothrombotic risk through systemic platelet activation, thrombin generation, endothelial 
dysfunction and inflammation 22–33 are more plausible explanations for the increased risk of 
MI with AF. Episodes of poorly controlled fast AF with uncontrolled ventricular response 
resulting in demand infarction, referred to as type-2 MI which typically occurs without ST 
elevation, could be another mechanism.
AF is an elusive rhythm that is hard to ascertain completely, especially in large population-
based studies. Moreover, different methods of AF ascertainment can lead to different 
prevalence estimates.34 Despite differences in the methods of AF ascertainment, the results 
in our ARIC analysis and REGARDS6 reached similar conclusions; AF is associated with 
increased risk of MI with potential sex and race differences in the magnitude of association. 
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This consistency in results across studies provides assurance that the association between 
AF and MI is not dependent on the method of AF ascertainment. Notably, the hazard ratios 
for MI associated with AF were similar in both ARIC and REGARDS.
Our observation that AF is associated with increased risk of MI in women more than men 
and possibly in blacks more than whites adds to the accumulating evidence of the sex and 
racial differences in CVD outcomes and the potential differences in the impact of risk 
factors among sexes and races. Since we adjusted for several potential confounders, it is less 
likely that our observed sex and racial differences were confounded by differences in AF 
associated morbidities. Future investigation should assess whether genetic background, 
emerging risk factors, access to healthcare, awareness and adherence to medications 
contribute to sex and racial differences. In the REGARDS study, we have previously shown 
that blacks and women are less likely to be aware of having AF or to be treated with 
warfarin.35 The excess risk of MI coupled with the tendency to under treat AF may magnify 
the risk of poor outcomes in these two groups.
Clinical and public health implications
The prevalence of AF doubles with each additional decade of life,36 and so we should 
expect the prevalence of AF-associated morbidity/mortality including MI also to grow 
according to our results. In an increasingly older population, such as the United States 
population, this may incur a substantial burden on the healthcare system. Efforts to increase 
awareness and detection of AF, especially in blacks and women, and the development of 
risk stratification tools to identify AF patients who are high risk for developing MI are 
needed.
From the prevention perspective, our results raise the question of whether anticoagulants 
could be effective in prevention of MI as they are for stroke. Results from different meta-
analyses among patients who had coronary artery disease suggest a potential reduction of MI 
risk in individuals receiving warfarin.37–41 In our study, however, the risk of MI was only 
attenuated by 3% after adjustment for warfarin, aspirin and statin use [i.e. HR reduced from 
1.66 in model 3 to 1.63 in model 4; Table 2]. Nevertheless, the relation between these 
medications and outcomes in our study should be interpreted with caution not only because 
they were self-reported which is subject to recall bias but also because they were only 
ascertained during study visits, introducing the potential for nonrandom misclassification. 
Also, whether the new generation of oral anticoagulants could have a role or will perform 
better than warfarin in prevention of MI in the setting of AF needs to be determined. The 
notion that AF potentiates thrombogenic risk through endothelial dysfunction and 
inflammation may highlight the potential importance of other therapeutic modalities that 
improve endothelial function and blunt the inflammatory response.
Strengths and limitations
Our results should be read in the context of certain limitations. Although we used two 
methods for AF ascertainment, study scheduled ECG and hospital discharge ICD codes, it 
remains possible that some paroxysmal/intermittent AF cases were not detected. However, 
this misclassification would likely attenuate the association between AF and MI and 
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subsequently our results should be considered as conservative. Also, most of AF cases in our 
study were detected through hospital discharge ICD codes. Thus, individuals with 
asymptomatic AF or those managed in an outpatient setting were more likely to remain 
unidentified. Nonetheless, the validity of hospital discharge codes for identifying incident 
AF in epidemiologic studies has previously been demonstrated.8, 10, 11
The number of blacks in the ARIC study may not be sufficient to examine black/white 
differences in the association between AF and MI. Hence, the non-significant interaction by 
race may be due to lack of statistical power.
Release of cardiac enzymes could be the result of non-ischemic causes (e.g. heart failure, 
myocarditis, etc.) or even non-cardiac causes (e.g. muscle trauma, rhabdomyolysis, etc.). 
Also, data on the timing of revascularization or thrombolysis during hospitalization for MI 
were not available to us which could have provided further insights into the unclassified MI 
cases. This could lead to misclassification of some cases of STEMI and non-STEMI. 
Nevertheless, as part of the standard procedures of MI ascertainment in ARIC,15 information 
on non-ischemic or non-cardiac causes for elevated cardiac enzymes during hospital 
admission for an MI is routinely abstracted from the discharge summary on the ARIC 
participants. This information is considered in the interpretation of the cardiac enzymes as 
part of the MI diagnosis. Therefore, it is unlikely that non-cardiac causes of elevated cardiac 
enzymes have resulted in significant misclassification of MI.
On a related note, the growing use of highly sensitive troponin in recent years has led to an 
increase in the rates of detection of MI compared to before. This raises the possibility of 
differences in the association between AF with MI in the early years compared to the later 
years of ARIC follow up. However, changes in the ability to diagnose MI over time would 
be more relevant for the study of trends, which requires assessment of absolute incidence 
rates of MI over time. In our case, this is less important unless we think that the changes in 
sensitivity to identify MI are going to be different in those with vs those without AF, which 
is unlikely, as supported by our results of the association between AF and MI at different 
periods of follow up (Supplemental Table 4)
Finally, similar to other studies, residual confounding and misclassification of the outcome 
always remain a possibility. For example, we could not adjust for left ventricular ejection 
fraction or valvular heart disease, which could confound our results. Nevertheless, we 
adjusted for heart failure, minimizing the concern of confounding by left ventricular 
function. Also events triggering AF or the follow-up of AF patients may further confound or 
increase the suspicion for MI diagnosis, which could also lead to an association of AF with 
MI.
Despite these limitations, our study, with its robust methodology, provides further evidence 
for a link between AF and MI and highlights the role of MI type in this association. Key 
strengths of our study include a large community-based cohort, long-term follow up, 
substantial number of MI events identified by rigorous physician adjudication, and the 
ability to use AF as time-updated variable.
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AF was associated with an increased risk of incident MI in the ARIC study. This association 
differed by MI type; AF was associated with an increased risk of NSTEMI but not STEMI. 
Sex differences in the association between AF and MI were also observed, with a stronger 
risk of MI associated with AF in women compared to men. While it is currently unknown 
whether AF prevention or use of anticoagulants will reduce MI risk, our findings extend AF 
complications beyond stroke and total mortality to include MI.
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Refer to Web version on PubMed Central for supplementary material.
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Unadjusted Kaplan Meier myocardial infarction free survival curves by atrial fibrillation 
status. *Time to event in the AF group is the time from detection of AF not the cohort 
inception.
Soliman et al. Page 13














Sex and race stratified age-adjusted incidence rates and incidence rate ratios of MI by AF 
status. MI= Myocardial infarction, AF= Atrial fibrillation. *Age-adjusted incidence rate 
ratio and incidence rates were based on the average age of the cohort (54 years). †Time to 
event in the AF group is the time from detection of AF not the cohort inception.
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